Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director · PRESIDENT, CEO | January 22, 2026 | January 26, 2026 |
| Zyla Life SciencesEGLT · Entity 148990 | Chief Medical Officer | June 08, 2017 | June 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,500 |
Reported balance
After 2026-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-24 · Exercise / conversion · Acquired 10,500 · Balance 10,500 |
| Common StockSEC Table I · non-derivative | Direct | 5,715 |
Reported balance
After 2026-01-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-24 · Tax withholding · Disposed 4,785 · Balance 5,715 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 13,000 |
Reported balance
After 2026-01-25 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-01-25 · Exercise / conversion · Acquired 13,000 · Balance 13,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,346 |
Reported balance
After 2026-01-25 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-01-25 · Tax withholding · Disposed 5,654 · Balance 7,346 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $36.76 · Expires 2036-01-22 | Direct | 184,600 |
Reported balance
After 2026-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-22 · Grant · Acquired 184,600 · Balance 184,600 F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,900 |
Reported balance
After 2026-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-22 · Grant · Acquired 52,900 · Balance 52,900 F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,000 |
Reported balance
After 2026-01-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-24 · Exercise / conversion · Disposed 10,500 · Balance 21,000 F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 39,000 |
Reported balance
After 2026-01-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-25 · Exercise / conversion · Disposed 13,000 · Balance 39,000 F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Zyla Life Sciences
Report date June 08, 2017 · Filed June 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2027-06-08 | Direct | 80,000 |
Reported balance
After 2017-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 80,000 · Balance 80,000 F1: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the options will vest on the later of (i) the 6-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $3.33 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. 25% of the options will vest on the later of (i) the 12-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.05 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date. The remaining 50% of the options will vest on the later of (i) the 24-month anniversary of the grant date and (ii) the date on which the average closing price of the Company's common stock on NASDAQ is at least $4.76 for 30 consecutive trading days, provided that the grantee remains employed by the Company on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · derivative · entry 8 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 13,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_price: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.expiration_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 5,654 | $36.82 | $208,180.28 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · nonDerivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,346 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · nonDerivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · derivative · entry 7 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 10,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 4,785 | $36.82 | $176,183.70 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,715 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 52,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · derivative · entry 6 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,900 Underlying: Common Stock · 52,900 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 16:43 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 184,600 | $0.00 Strike: $36.76 | $0.00 |
DisclosureSEC source: 0001615993-26-000002 · form4-01262026_090130.xml · derivative · entry 5 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,600 Underlying: Common Stock · 184,600 shares Expires 2036-01-22 F2 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 17:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001615993-25-000005 · form4-12172025_051201.xml · derivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on November 1, 2018. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 17:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,933 | $40.11 | $237,956.61 |
DisclosureSEC source: 0001615993-25-000005 · form4-12172025_051201.xml · nonDerivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.28. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 17:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 20,000 | $40.11 | $802,146.00 |
DisclosureSEC source: 0001615993-25-000005 · form4-12172025_051201.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.28. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 17:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 20,000 | $8.22 | $164,400.00 |
DisclosureSEC source: 0001615993-25-000005 · form4-12172025_051201.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002159 · form4-01282025_090137.xml · derivative · entry 5 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires not disclosed F4 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 180,000 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001415889-25-002159 · form4-01282025_090137.xml · derivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-01-25 F3 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002159 · form4-01282025_090137.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 10,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 4,567 | $38.01 | $173,591.67 |
DisclosureSEC source: 0001415889-25-002159 · form4-01282025_090137.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,933 F1 · date: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 16:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002159 · form4-01282025_090137.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 9,737 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-25-001931 · form4-01232025_090139.xml · derivative · entry 5 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,435 Underlying: Common Stock · 9,737 shares Expires 2030-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on March 1, 2021. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 6,086 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-25-001931 · form4-01232025_090139.xml · derivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,086 shares Expires 2029-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on January 1, 2020. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 3,470 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-25-001931 · form4-01232025_090139.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 3,470 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on November 1, 2018. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 19,293 | $40.13 | $774,245.45 |
DisclosureSEC source: 0001415889-25-001931 · form4-01232025_090139.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.50. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 16:17 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 19,293 | $8.22 | $158,588.46 |
DisclosureSEC source: 0001415889-25-001931 · form4-01232025_090139.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:56 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001872 · form4-01262024_090119.xml · derivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 16:56 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 202,250 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-24-001872 · form4-01262024_090119.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,250 Underlying: Common Stock · 202,250 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| May 26, 2023 Filed May 30, 2023 16:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 125,000 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001415889-23-008914 · form4-05302023_080517.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The stock option vests with respect to 50% of the underlying shares on May 25, 2025, with the remaining shares vesting in twenty-four equal monthly installments beginning on June 25, 2025. Read SEC document |
| May 26, 2023 Filed May 31, 2023 16:37 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 125,000 | $0.00 Strike: $35.56 | $0.00 |
DisclosureSEC source: 0001415889-23-008971 · form4a-05312023_080505.xml · derivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Director · PRESIDENT, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-05-25 F1 · derivative.exercise_price: This Form 4/A is being filed to amend the exercise price of the granted options previously reported as being $35.99 to $35.56. F2 · derivative.exercise_date: The stock option vests with respect to 50% of the underlying shares on May 25, 2025, with the remaining shares vesting in twenty-four equal monthly installments beginning on June 25, 2025. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 16:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-011083 · form4-11042022_041101.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 Underlying: Common Stock · 15,000 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on November 1, 2018. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 16:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 15,000 | $60.02 | $900,331.50 |
DisclosureSEC source: 0001415889-22-011083 · form4-11042022_041101.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.23. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 16:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $8.22 | $123,300.00 |
DisclosureSEC source: 0001415889-22-011083 · form4-11042022_041101.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 16:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 15,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-010986 · form4-11022022_011117.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,470 Underlying: Common Stock · 15,000 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in five equal annual installments beginning on November 1, 2018. F4 · balance_after: The Form 4 filed by the reporting person on October 20, 2021, understated the number of securities owned following the reported transaction by 1 share. The amount of securities reported herein reflects the correct number of securities owned following the transactions reported on this Form 4. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 16:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 15,000 | $55.10 | $826,558.50 |
DisclosureSEC source: 0001415889-22-010986 · form4-11022022_011117.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.00 to $55.62. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 2, 2022 16:04 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 15,000 | $8.22 | $123,300.00 |
DisclosureSEC source: 0001415889-22-010986 · form4-11022022_011117.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 4,101 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · derivative · entry 6 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,469 Underlying: Common Stock · 4,101 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 14,099 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · derivative · entry 5 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,570 Underlying: Common Stock · 14,099 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,101 | $43.77 | $179,506.51 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.99. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 4,101 | $8.22 | $33,710.22 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 14,099 | $43.13 | $608,036.29 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.65 to $43.63. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 21:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 14,099 | $8.22 | $115,893.78 |
DisclosureSEC source: 0001104659-21-128203 · tm2129561-2_4seq1.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 18:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 1,800 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,669 Underlying: Common Stock · 1,800 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 18:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,800 | $40.10 | $72,178.56 |
DisclosureSEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.075 to $40.41. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 18:55 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 1,800 | $8.22 | $14,796.00 |
DisclosureSEC source: 0001104659-21-124273 · tm2129561-1_4seq1.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-035505 · doc4.xml · derivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,469 Underlying: Common Stock · 10,000 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 62,082 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on November 1, 2021. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 10,000 | $37.58 | $375,783.00 |
DisclosureSEC source: 0000899243-21-035505 · doc4.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.78. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 21:23 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,000 | $8.22 | $82,200.00 |
DisclosureSEC source: 0000899243-21-035505 · doc4.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 7,841 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · derivative · entry 6 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,469 Underlying: Common Stock · 7,841 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 7,841 | $35.16 | $275,700.54 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 4 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 7,841 | $8.22 | $64,453.02 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 3 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 2,159 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · derivative · entry 5 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,310 Underlying: Common Stock · 2,159 shares Expires 2027-11-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 82,777 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 13, 2021. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,159 | $35.01 | $75,581.19 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 2 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.09. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 26, 2021 Filed Aug 30, 2021 16:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,159 | $8.22 | $17,746.98 |
DisclosureSEC source: 0000899243-21-034517 · doc4.xml · nonDerivative · entry 1 Dayno Jeffrey M. · CIK 0001615993 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.